Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Driponin is a brand name for a pharmaceutical product containing ivermectin as its active ingredient. Ivermectin is an anthelmintic (anti-parasitic) agent used primarily to treat infections caused by certain parasites, including strongyloidiasis (intestinal threadworm infection) and onchocerciasis (river blindness). The drug works by binding selectively and with high affinity to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates, leading to paralysis and death of the parasite. Driponin tablets contain 3 mg of ivermectin per tablet. While ivermectin has been studied for other indications such as COVID-19 prophylaxis, it is not approved for this use in most countries[4][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on driponin.